Skip to main content Skip to section navigation Skip to footer
Morphogenesis Inc. morphogenesis logo white morphogenesis logo color
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline & Technologies
    • Overview
    • Our Technologies
    • IFx-Hu2.0
    • IFx-Hu3.0
    • Tumor Microenvironment Modulators
    • Scientific Publications
  • Patient Resources
    • Overview
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Contact

Scientific Publications

Morphogenesis, Inc. and CohBar, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

CohBar Website

Access Webcast Replay
Pipeline & Technologies

Pipeline & Technologies

  • Overview
  • Our Technologies
  • IFx-Hu2.0
  • IFx-Hu3.0
  • Tumor Microenvironment Modulators
  • Scientific Publications

Tumor-specific antibody response induced by novel immunomodulator, IFx-Hu2.0, reflects extent of epitope spreading to multiple tumor epitopes

View PDF https://d1io3yog0oux5.cloudfront.net/_53d289dcac33be537131337a3b683227/morphogenesisinc/db/2306/20861/pdf/AACR2022+final+poster+03212022+Amanda+Laubscher.pdf View Article https://aacrjournals.org/cancerres/article/82/12_Supplement/5199/703221/Abstract-5199-Tumor-specific-antibody-response

Exosome packaging of emm55 mRNA

View PDF https://d1io3yog0oux5.cloudfront.net/_53d289dcac33be537131337a3b683227/morphogenesisinc/db/2306/20860/pdf/Exosome+packaging+of+emm55+mRNA+Abstract+20211110+Amanda+Laubscher.pdf

Anti‑tumor efficacy of plasmid encoding emm55 in a murine melanoma model

View PDF https://d1io3yog0oux5.cloudfront.net/_53d289dcac33be537131337a3b683227/morphogenesisinc/db/2306/20859/pdf/Bunch2020_Article_Anti-tumorEfficacyOfPlasmidEnc+Amanda+Laubscher.pdf View Article https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680263/

Trial in progress: IFx Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma

View PDF https://d1io3yog0oux5.cloudfront.net/_53d289dcac33be537131337a3b683227/morphogenesisinc/db/2306/20858/pdf/Markowitz_AACR_04122020_revised1+Amanda+Laubscher.pdf View Article https://aacrjournals.org/cancerres/article/80/16_Supplement/CT241/645158/Abstract-CT241-Trial-in-progress-IFx-Hu2-0-plasmid

First in human Phase I study using a plasmid DNA coding for Emm55 streptococcal antigen (IFx-Hu2.0) in patients with unresectable stage III or stage IV cutaneous melanoma

View PDF https://d1io3yog0oux5.cloudfront.net/_53d289dcac33be537131337a3b683227/morphogenesisinc/db/2306/20857/pdf/AACR+2019+Markowitz_Morphogenesis_march192019JM-AD+Amanda+Laubscher.pdf View Article https://aacrjournals.org/cancerres/article/79/13_Supplement/CT119/637715/Abstract-CT119-Trial-in-progress-First-in-human

Autologous Tumor Cells Engineered to Express Bacterial Antigens

View PDF https://d1io3yog0oux5.cloudfront.net/_53d289dcac33be537131337a3b683227/morphogenesisinc/db/2306/20856/pdf/Chapter+21+Cancer+Vaccines+Amanda+Laubscher.pdf View Article https://link.springer.com/protocol/10.1007/978-1-4939-0345-0_21

Treatment of Metastatic Equine Melanoma with a Plasmid DNA Vaccine Encoding Streptococcus Pyogenes EMM55 Protein

View PDF https://d1io3yog0oux5.cloudfront.net/_53d289dcac33be537131337a3b683227/morphogenesisinc/db/2306/20855/pdf/J+Equine+Vet+Treatment+of+Equine+Melanoma+Amanda+Laubscher.pdf View Article https://www.sciencedirect.com/science/article/abs/pii/S0737080613009088

Anti-tumor response induced by autologous cancer vaccine in canine lymphoma

View Article https://web.p.ebscohost.com/abstract?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=15439135&AN=37796315&h=0IWRzubiRuHEhLWO%2f7WSOrGJZLCIcLoPOFfLoX9wkXtuEnR22fzQVIP1HFX6Utu1ZuL%2f3qux4qjrxsuRdgpKIQ%3d%3d&crl=c&resultNs=AdminWebAuth&resultLocal=ErrCrlNotAuth&crlhashurl=login.aspx%3fdirect%3dtrue%26profile%3dehost%26scope%3dsite%26authtype%3dcrawler%26jrnl%3d15439135%26AN%3d37796315

Anti-Tumor Response Induced By Autologous Cancer Canine In Canine Lymphoma: A Case Study

View PDF https://d1io3yog0oux5.cloudfront.net/_53d289dcac33be537131337a3b683227/morphogenesisinc/db/2306/20853/pdf/VCS+2007+Poster+Amanda+Laubscher.pdf

Clinical Response to Multi-indication Intralesional Immunotherapy for Malignant Melanoma

View PDF https://d1io3yog0oux5.cloudfront.net/_53d289dcac33be537131337a3b683227/morphogenesisinc/db/2306/20852/pdf/VCS+Clinical+Poster+FInal_MG_20160930+Amanda+Laubscher.pdf
  • Page 1
  • Page 2
  • Next Pagearrow_forward
©2023 Morphogenesis Inc. All Rights Reserved.
Privacy Policy Sitemap Terms of Use